Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: Randomized controlled trial (birmingham atrial fibrillation treatment of the aged study)

Stroke

Volumn 45, Issue 5, 2014, Pages 1381-1386

  Mavaddat, Nahal ^a   Roalfe, Andrea ^b   Fletcher, Kate ^b   Lip, Gregory Y H ^b   Hobbs, F D Richard ^c   Fitzmaurice, David ^b   Mant, Jonathan ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Aspirin; Atrial fibrillation; Cognition; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OPEN STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; ATRIAL FIBRILLATION; COGNITION; WARFARIN;

AGED; AGED, 80 AND OVER; AGING; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COGNITION DISORDERS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84899960874     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.004009     Document Type: Article

References (29)

1. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006-1018.
2. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914-922.
3. Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184:E329-E336.
4. Jozwiak A, Guzik P, Mathew A, Wykretowicz A, Wysocki H. Association of atrial fibrillation and focal neurologic deficits with impaired cognitive function in hospitalized patients >or=65 years of age. Am J Cardiol. 2006;98:1238-1241.
5. Puccio D, Novo G, Baiamonte V, Nuccio A, Fazio G, Corrado E, et al. Atrial fibrillation and mild cognitive impairment: what correlation? Minerva Cardioangiol. 2009;57:143-150.
6. Wozakowska-Kapłon B, Opolski G, Kosior D, Jaskulska-Niedziela E, Maroszyńska-Dmoch E, Włosowicz M. Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol. 2009;67:487-493.
7. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28:316-321.
8. Knecht S, Oelschläger C, Duning T, Lohmann H, Albers J, Stehling C, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29:2125-2132.
9. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
10. Mant JW, Richards SH, Hobbs FD, Fitzmaurice D, Lip GY, Murray E et al. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. BMC Cardiovasc Disord 2003;3:9.
11. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
12. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry. 1983;140:734-739.
13. Brooke P, Bullock R. Validation of a 6 item cognitive impairment test with a view to primary care usage. Int J Geriatr Psychiatry. 1999;14:936-940.
14. Folstein MF, Folstein SE. "Mini-Mental State" A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975;12:189-98.
15. Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination. J Neurol Neurosurg Psychiatry. 2007;78:1298-1303.
16. Rubin D. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.
17. Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. J Clin Epidemiol. 2005;58: 13-19.
18. Stein J, Luppa M, Brähler E, König HH, Riedel-Heller SG. The assessment of changes in cognitive functioning: reliable change indices for neuropsychological instruments in the elderly - a systematic review. Dement Geriatr Cogn Disord. 2010;29:275-286.
19. Stein J, Luppa M, Maier W, Wagner M, Wolfsgruber S, Scherer M, et al; AgeCoDe Study Group. Assessing cognitive changes in the elderly: reliable change indices for the Mini-Mental State Examination. Acta Psychiatr Scand. 2012;126:208-218.
20. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.
21. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta- analysis of observational studies. BMJ. 2003;327:128.
22. Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry. 1997;62:269-272.
23. Terrera GM, Brayne C, Matthews F; CC75C Study Collaboration Group. One size fits all? Why we need more sophisticated analytical methods in the explanation of trajectories of cognition in older age and their potential risk factors. Int Psychogeriatr. 2010;22:291-299.
24. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
25. MRC CFAS. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFAS Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Psychol Med. 1998;28:319-335.
26. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369-2429.
27. Puccio D, Novo G, Baiamonte V, Nuccio A, Fazio G, Corrado E, et al. Atrial fibrillation and mild cognitive impairment: what correlation? Minerva Cardioangiol. 2009;57:143-150.
28. Doucet J, Gréboval-Furstenfeld E, Tavildari A, M'bello L, Delaunay O, Pesqué T, et al. Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. Fundam Clin Pharmacol. 2008;22:569-574.
29. Park H, Hildreth A, Thomson R, O'Connell J. Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study. Age Ageing. 2007;36:157-163.